October 22, 2007
| 4. | Post-Share Exchange Situation | |
| A. Kyowa Hakko Kogyo Co., Ltd. | ||
| (1) | Trade Name Kyowa Hakko Kogyo Co., Ltd. |
|
| (2) | Main Business Production and sales of pharmaceutical products for medical professionals, raw materials for industrial and pharmaceutical use, healthcare products, products for the agriculture and livestock industry and the fishing industry, alcohol, etc. |
|
| (3) | Address of Head Office 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo |
|
| (4) | Name and Title of Representative (scheduled) Yuzuru Matsuda, President and CEO |
|
| (5) | Paid-in Capital Not yet determined. |
|
| (6) | Total Assets Not yet determined. |
|
| (7) | Net Assets Not yet determined. |
|
| (8) | Fiscal Year End March 31 |
|
| (9) | Summary of Accounting Procedure Although Kirin Pharma will become the wholly owned subsidiary of Kyowa Hakko as the result of the Share Exchange, since Kyowa Hakko will become a subsidiary of Kirin Holdings, for the purpose of accounting for business combinations, the Share Exchange is accounted for as a reverse acquisition with Kirin Pharma as the acquiring company of Kyowa Hakko. Accordingly, the purchase method will apply with respect to the consolidated financial statements after the Share Exchange, and goodwill will be generated as a result of the Share Exchange. The value of the goodwill and the period of amortization have not been determined at this time. |
|
| (10) | Outlook for impact of Share Exchange on business results The outlook for the business results, as well as the value of the goodwill and the years of depreciation have not been determined at this time. The outlook will be disclosed as soon as it is determined. |
|
| B. Kirin Holdings Company, Limited | ||
| (1) | Trade Name Kirin Holdings Company, Limited |
|
| (2) | Main Business As a holding company, Kirin Holdings controls and manages the business activities of its business corporations (which engage in businesses such as alcohol, beverages and pharmaceutical products). |
|
| (3) | Address of Head Office 2-10-1 Shinkawa, Chuo-ku, Tokyo |
|
| (4) | Name and Title of Representative (scheduled) Kazuyasu Kato, President and CEO |
|
| (5) | Paid-in Capital Not yet determined. |
|
| (6) | Total Assets Not yet determined. |
|
| (7) | Net Assets Not yet determined. |
|
| (8) | Fiscal Year End December 31 |
|
| (9) | Summary of Accounting Procedure as a Consolidated Company For the purposes of accounting for business combinations, the purchase method will be applied and goodwill will be reported. The value of the goodwill and the period of amortization have not been determined at this time. Any goodwill generated shall be amortized in accordance with the straight line method during the period within which the effect is estimated to develop. |
|
| (10) | Outlook for impact of Share Exchange on business results The outlook for the business results, as well as the value of the goodwill and the years of depreciation have not been determined at this time. The outlook will be disclosed as soon as it is determined. |
|
| C. Kirin Pharma Company, Limited | ||
| (1) | Trade Name Kirin Pharma Company, Limited |
|
| (2) | Main Business Manufacture and Sale of pharmaceutical products |
|
| (3) | Address of Head Office 6-26-1 Jingumae, Shibuya-ku, Tokyo |
|
| (4) | Name and Title of Representative (scheduled) Katsuhiko Asano, President and Chairman of the Board of Directors |
|
| (5) | Paid-in Capital Not yet determined. |
|
| (6) | Total Assets Not yet determined. |
|
| (7) | Net Assets Not yet determined. |
|
| (8) | Fiscal Year End December 31 |
|
